(RTTNews) - Rhythm Pharmaceuticals, Inc. (RYTM) Friday said it expects full-year product revenue of about $130 million, higher than $77.4 million reported in the previous year.
For the fourth quarter, the company sees revenues from sales of IMCIVREE (setmelanotide) to be approximately $42 million, 26 percent higher than the previous quarter.
The company also added that it is on track to report topline data from the pivotal Phase 3 trial evaluating setmelanotide in acquired Hypothalamic Obesity (HO) in the first half of 2025.
The company plans to report its fourth quarter results in late February.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
